Cited by 336Renal cell carcinoma treatmentCancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma

Open access

Kaelin, William G.·2007·Clinical Cancer Research

Open this paper in CoChat — free account Open PDF

Abstract

Germ line VHL tumor suppressor gene loss-of-function mutations cause von Hippel-Lindau disease, which is associated with an increased risk of central nervous system hemangioblastomas, clear cell renal carcinomas, and pheochromocytomas. Somatic VHL mutations are also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the α-subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for polyubiquitylation, and hence, proteasomal degradation, when oxygen is available. pVHL-defective clear cell renal carcinomas overproduce a variety of mRNAs that are under the control of HIF, including the mRNAs that encode vascular endothelial growth factor, platelet-derived growth factor B, and transforming growth factor α. In preclinical models, down-regulation of HIF-α, especially HIF-2α, is both necessary and sufficient for renal tumor suppression by pVHL. These observations are probably relevant to the demonstrated clinical activity of vascular endothelial growth factor antagonists in clear cell renal carcinoma and form a foundation for the testing of additional agents that inhibit HIF, or HIF-responsive gene products, in this disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-1865

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citation
Untitled work
(2000) · PubMed · Cited by 1,445
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,234
Hypoxia of the Renal Medulla — Its Implications for Disease
Brezis, M., & Rosen, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321006 · Cited by 1,229
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein
Cockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G.-W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J., & Maxwell, P. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002740200 · Cited by 1,053
Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation
Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.18.5197 · Cited by 1,014
Role of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 955
Self-citation
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein
Tanimoto, K., Makino, Y., Pereira, T., & Poellinger, L. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4298 · Cited by 928
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 896
Self-citation
Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870
Molecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Self-citation
HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation
Yu, F., White, S. B., Zhao, Q., & Lee, F. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181341498 · Cited by 796
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citation
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 737
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A. S., Gray, S. G., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 710
Self-citation
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705
Hsp90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02316-x · Cited by 677
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex
Kamura, T., Sato, S., Iwaï, K., Czyzyk-Krzeska, M., Conaway, R. C., & Conaway, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190332597 · Cited by 652
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611
Self-citation
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
Ivan, M., Haberberger, T., Gervasi, D. C., Michelson, K. S., Günzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R. C., Conaway, J. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192342099 · Cited by 561
Self-citation
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
Gnarra, J. R., Zhou, S., Merrill, M. J., WAGNER, J. R., Krumm, A., Papavassiliou, E. D., Oldfield, E. H., Klausner, R. D., & Linehan, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10589 · Cited by 531
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00187-9 · Cited by 528
Self-citation
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer
Lee, S., Nakamura, E., Yang, H., Wei, W., Linggi, M. S., Sajan, M. P., Farese, R. V., Freeman, R. S., Carter, B. D., Kaelin, W. G., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.015 · Cited by 527
Self-citation
HIF activation identifies early lesions in VHL kidneys
Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00071-5 · Cited by 483
A Novel Hypoxia-inducible Factor-independent Hypoxic Response Regulating Mammalian Target of Rapamycin and Its Targets
Arsham, A. M., Howell, J. J., & Simon, M. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212770200 · Cited by 463
Silencing of Epidermal Growth Factor Receptor Suppresses Hypoxia-Inducible Factor-2–Driven VHL −/− Renal Cancer
Smith, K., Gunaratnam, L., Morley, M., Franovic, A., Mekhail, K., & Lee, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0169 · Cited by 457
The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma
Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00044-2 · Cited by 442
Vascular tumors in livers with targeted inactivation of the von Hippel–Lindau tumor suppressor
Haase, V. H., Glickman, J. N., Socolovsky, M., & Jaenisch, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1583 · Cited by 430
Hypoxia-Inducible Factor-1-Dependent Repression of E-cadherin in von Hippel-Lindau Tumor Suppressor–Null Renal Cell Carcinoma Mediated by TCF3, ZFHX1A, and ZFHX1B
Krishnamachary, B., Zagzag, D., Nagasawa, H., Rainey, K., Okuyama, H., Baek, J. H., & Semenza, G. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3719 · Cited by 415
Inhibitory PAS Domain Protein (IPAS) Is a Hypoxia-inducible Splicing Variant of the Hypoxia-inducible Factor-3α Locus
Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H., & Poellinger, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200328200 · Cited by 383
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
Clifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice
Gnarra, J. R., Ward, J. M., Porter, F. D., WAGNER, J. R., Devor, D. E., Grinberg, A., Emmert‐Buck, M. R., Westphal, H., Klausner, R. D., & Linehan, W. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9102 · Cited by 366
Renal Cyst Development in Mice with Conditional Inactivation of the von Hippel-Lindau Tumor Suppressor
Rankin, E. B., Tomaszewski, J. E., & Haase, V. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3241 · Cited by 364
Hypoxia-Inducible Factor-1-Dependent Repression of E-cadherin in von Hippel-Lindau Tumor Suppressor—Null Renal Cell Carcinoma Mediated by TCF3, ZFHX1A, and ZFHX1B
Gordon, M. S. (2007) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)70352-x · Cited by 343
A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size.
Zhuang, Z., Bertheau, P., Emmert-Buck, M. R., Liotta, L. A., Gnarra, J. R., Linehan, W. M., & Lubensky, I. A. (1995) · Europe PMC (PubMed Central) · Cited by 262
Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor
Zagzag, D., Krishnamachary, B., Yee, H. T., Okuyama, H., Chiriboga, L. A., Ali, M., Melamed, J., & Semenza, G. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4406 · Cited by 259
Coordinate Regulation of the Oxygen-Dependent Degradation Domains of Hypoxia-Inducible Factor 1α
Chan, D. A., Sutphin, P. D., Yen, S., & Giaccia, A. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.15.6415-6426.2005 · Cited by 248
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors
Zimmer, M., Doucette, D., Siddiqui, N., & Iliopoulos, O. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.89.2.2 · Cited by 244
The von Hippel–Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
Pause, A., Lee, S., Lonergan, K. M., & Klausner, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.993 · Cited by 237
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
Kim, W. Y., Safran, M., Buckley, M. R., Ebert, B. L., Glickman, J., Bosenberg, M., Regan, M., & Kaelin, W. G. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601300 · Cited by 235
Self-citation
A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., O’Toole, T. E., Kong, S., & Moore, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.lba4 · Cited by 210
Human HIF‐3α4 is a dominant‐negative regulator of HIF‐1 and is down‐regulated in renal cell carcinoma
Maynard, M. A., Evans, A. J., Hosomi, T., Hara, S., Jewett, M. A. S., & Ohh, M. (2005) · The FASEB Journal · doi:10.1096/fj.05-3788com · Cited by 205
The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells
Koochekpour, S., Jeffers, M., Wang, P. H., Gong, C., Taylor, G. A., Roessler, L. M., Stearman, R. S., Vasselli, J. R., Stetler‐Stevenson, W. G., Kaelin, W. G., et al. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5902 · Cited by 201
Self-citation
Role of transforming growth factor-alpha in von Hippel- Lindau (VHL)-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
de Paulsen, N., Brychzy, A., Fournier, M.-C., Klausner, R. D., Gnarra, J. R., Pause, A., & Lee, S. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1387 · Cited by 196
Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinoma
Petrella, B. L., Lohi, J., & Brinckerhoff, C. (2004) · Oncogene · doi:10.1038/sj.onc.1208305 · Cited by 195
Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky, I. A., Gnarra, J. R., Bertheau, P., Walther, M. M., Linehan, W. M., & Zhuang, Z. (1996) · PubMed Central · Cited by 187
The von Hippel-Lindau Tumor Suppressor Protein Mediates Ubiquitination of Activated Atypical Protein Kinase C
Okuda, H., Saitoh, K., Hirai, S.-I., Iwaï, K., Takaki, Y., Baba, M., Minato, N., Ohno, S., & Shuin, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107880200 · Cited by 177
Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann, B., Karumanchi, S. A., Cohen, H. T., & Sukhatme, V. P. (1998) · PubMed · Cited by 170
Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
Karumanchi, S. A., Knebelmann, B., Grüning, W., Dhanabal, M., Walz, G., Stillman, I. E., & Sukhatme, V. P. (1999) · PubMed · Cited by 147
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease
Zatyka, M., da Silva, N. F., Clifford, S. C., Morris, M. R., Wiesener, M. S., Eckardt, K., Houlston, R. S., Richards, F. M., Latif, F., & Maher, E. R. (2002) · PubMed · doi:10.25405/ncl.34582002 · Cited by 147
Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells
Oya, M., Ohtsubo, M., Takayanagi, A., Tachibana, M., Shimizu, N., & Murai, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204525 · Cited by 146
The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways
Pal, S., Claffey, K. P., Dvorak, H. F., & Mukhopadhyay, D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.27509 · Cited by 144
Inactivation of the Arylhydrocarbon Receptor Nuclear Translocator (Arnt) Suppresses von Hippel-Lindau Disease-Associated Vascular Tumors in Mice
Rankin, E. B., Higgins, D. F., Walisser, J. A., Johnson, R. S., Bradfield, C. A., & Haase, V. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3163-3172.2005 · Cited by 140
VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
Bindra, R. S., Vasselli, J. R., Stearman, R. S., Linehan, W. M., & Klausner, R. D. (2002) · PubMed · Cited by 127
Characterization of a von Hippel Lindau Pathway Involved in Extracellular Matrix Remodeling, Cell Invasion, and Angiogenesis
Kurban, G., Hudon, V., Duplan, E., Ohh, M., & Pause, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2560 · Cited by 126
Increased nuclear factor-κB activation is related to the tumor development of renal cell carcinoma
Oya, M., Takayanagi, A., Horiguchi, A., Mizuno, R., Ohtsubo, M., Marumo, K., Shimizu, N., & Murai, M. (2003) · Carcinogenesis · doi:10.1093/carcin/24.3.377 · Cited by 123
The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi, H., & Ohh, M. (2003) · PubMed · Cited by 119
Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity
An, J., & Rettig, M. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7546-7556.2005 · Cited by 118
Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene.
Ma, W., Tessarollo, L., Hong, S., Baba, M., Southon, E. A., Back, T. C., Spence, S. E., Lobe, C. G., Sharma, N. D., Maher, G., et al. (2003) · PubMed · Cited by 112
Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor
Baba, M., Hirai, S., Yamada‐Okabe, H., Hamada, K., Tabuchi, H., Kobayashi, K., Kondo, K., Yoshida, M., Yamashita, A., Kishida, T., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206373 · Cited by 112
VHL Induces Renal Cell Differentiation and Growth Arrest through Integration of Cell-Cell and Cell-Extracellular Matrix Signaling
Davidowitz, E. J., Schoenfeld, A. R., & Burk, R. D. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.865-874.2001 · Cited by 106
Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes
Okuda, H., Hirai, S.-I., Takaki, Y., Kamada, M., Baba, M., Sakai, N., Kishida, T., Kaneko, S., Yao, M., Ohno, S., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1347 · Cited by 99
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
Lieubeau, B., Rak, J. W., Jothy, S., Iliopoulos, O., Kaelin, W. G., & Kerbel, R. S. (1998) · PubMed · Cited by 91
Self-citation
von Hippel-Lindau Tumor Suppressor Protein Regulates the Assembly of Intercellular Junctions in Renal Cancer Cells through Hypoxia-Inducible Factor–Independent Mechanisms
Calzada, M. J., Esteban, M. A., Feijoo‐Cuaresma, M., Castellanos, M. C., Naranjo‐Suarez, S., Temes, E., Méndez, F., Yáñez‐Mó, M., Ohh, M., & Landázuri, M. O. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3236 · Cited by 77
Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1α in human salivary gland cancer cells
Hara, S., Nakashiro, K., Klosek, S. K., Ishikawa, T., Shintani, S., & Hamakawa, H. (2006) · Oral Oncology · doi:10.1016/j.oraloncology.2005.10.016 · Cited by 75
Renal cell carcinoma risk in type 2 von Hippel–Lindau disease correlates with defects in pVHL stability and HIF-1α interactions
Knauth, K., Bex, C., Jemth, P., & Buchberger, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209062 · Cited by 74
VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-κB-dependent mechanism
An, J., Fisher, M., & Rettig, M. B. (2004) · Oncogene · doi:10.1038/sj.onc.1208348 · Cited by 59
Up-Regulation ofc-metProtooncogene Product Expression through Hypoxia-Inducible Factor-1α Is Involved in Trophoblast Invasion under Low-Oxygen Tension
Hayashi, M., Sakata, M., Takeda, T., Tahara, M., Yamamoto, T., Okamoto, Y., Minekawa, R., Isobe, A., Ohmichi, M., Tasaka, K., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0416 · Cited by 56

Sorted by citations

HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P. J., Cohen, P. A., Golshayan, A., Rayman, P. A., Wood, L. S., García, J. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 861
Hypoxia and cancer
Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765
Targeting the ubiquitin system in cancer therapy
Hoeller, D., & Đikić, I. (2009) · Nature · doi:10.1038/nature07960 · Cited by 605
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling
Adam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G. W., Wolhuter, K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.006 · Cited by 585

See all 336

Authors: Kaelin, W. G.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Kaelin, William G.
ORCID: Kaelin, William G.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2007-01-15
Volume: 13
Issue: 2
Pages: 680s-684s
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-06-1865
OpenAlex: W2131473358
Semantic Scholar: b1ecaaf13be1baca02f75edb325c7d80e991f9a6
Cited by: 336
References: 80
Citations by year: 2026: 13 · 2025: 13 · 2024: 6 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 9 · 2019: 9 · 2018: 14 · 2017: 13 · 2016: 14 · 2015: 14 · 2014: 18 · 2013: 18 · 2012: 28
FWCI: 5.33
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords: von Hippel-Lindau protein, VHL tumor suppressor, clear cell renal cell carcinoma, hypoxia-inducible factor, HIF-2α, HIF-1α, ubiquitin ligase, vascular endothelial growth factor, platelet-derived growth factor B, transforming growth factor-alpha, VEGF inhibitors, von Hippel-Lindau disease
MeSH terms: Carcinoma, Renal Cell, Genotype, Humans, Kidney Neoplasms, Mutation, RNA, Messenger, Transcription Factors, Signal Transduction, Gene Expression Regulation, Neoplastic, Dimerization, Vascular Endothelial Growth Factor A, Von Hippel-Lindau Tumor Suppressor Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks